Sotirios Tsiodras

National and Kapodistrian University of Athens

Also affiliated with University General Hospital Attikon

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “The benefits, costs and feasibility of a low incidence COVID-19 strategy”.

The benefits, costs and feasibility of a low incidence COVID-19 strategy

The Lancet Regional Health - Europe(2022)10.1016/j.lanepe.2021.100294

N/A

1.3DataRank · unranked

23 citations

Emil N. Iftekhar, Barbara Prainsack, Viola Priesemann, Simon Bauer, André Calero Valdez +18 more

Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

eClinicalMedicine(2023)10.1016/j.eclinm.2023.101871

N/A

0.626DataRank · unranked

64 citations

Jose M. Bravo-Ferrer, María Paniagua‐García, Tomislav Kostyanev, Marlieke E.A. de Kraker, Jan Feifel +119 more

Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma

Viruses(2021)10.3390/v13091844

N/A

0.434DataRank · unranked

8 citations

Margherita Rosati, Evangelos Terpos, Dimitris Stellas, Xintao Hu, Sevasti Karaliota +23 more

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial

Journal of Infection(2024)10.1016/j.jinf.2024.106120

N/A

0.345DataRank · unranked

9 citations

Clément R. Massonnaud, Eva Larranaga Lapique, Drifa Belhadi, Simon Jamard, François Goehringer +81 more

Autoantibodies are highly prevalent in non–SARS-CoV-2 respiratory infections and critical illness

JCI Insight(2023)10.1172/jci.insight.163150

N/A

0DataRank · unranked

28 citations

Emily Yu-Ann Yang, A. R. Moore, Shaurya Dhingra, Sarah E. Chang, Xihui Yin +38 more

The benefits, costs and feasibility of a low incidence COVID-19 strategy.

Edinburgh Research Explorer (University of Edinburgh)(2022)10.17863/cam.81311

N/A

0DataRank · unranked

29 citations

Emil N. Iftekhar, Barbara Prainsack, Viola Priesemann, Simon Bauer, André Calero Valdez +18 more

Microbiota-based markers predictive of development of Clostridioides difficile infection

Nature Communications(2021)10.1038/s41467-021-22302-0

N/A

0DataRank · unranked

89 citations

Mohamed Mysara, Basil Britto Xavier, Cornelis H. van Werkhoven, Pieter Monsieurs, Christine Lammens +52 more

Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study

Microorganisms(2020)10.3390/microorganisms8121885

N/A

0DataRank · unranked

43 citations

Marianna Politou, Theodoros Ν. Sergentanis, Αndreas Mentis, Margherita Rosati, Dimitris Stellas +28 more

Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections.

Research Square(2022)10.21203/rs.3.rs-1233038/v1

N/A

0DataRank · unranked

9 citations

Emily Yu-Ann Yang, A. R. Moore, Shaurya Dhingra, Sarah E. Chang, Xihui Yin +38 more